CAR- T and cellular genetics therapies are also costly

.Nature Medicine, Released online: 04 September 2024 doi:10.1038/ s41591-024-03231-zPoint-of-care manufacturing and technology move may supply cell gene therapies at a budget-friendly expense to patients throughout the world.